Background: Our genome sequencing analysis revealed a frameshift mutation in the shelterin gene TINF2 in a large family with individuals affected with papillary thyroid carcinoma (PTC) and melanoma. Here, we further characterized the mutation and screened for coding variants in the 6 shelterin genes in 24 families. Methods: Sanger sequencing was performed to screen for the TINF2 mutation in the key family. Quantitative reverse transcription-polymerase chain reaction (PCR) was used for TINF2 gene expression analysis. Exogenous expression and co-immunoprecipitation techniques were used for assessing TINF2 binding to TERF1. Relative telomere length (RTL) was quantified in DNAs from lymphocytes by using quantitative real-time PCR. Whole exome sequencing (WES) was performed in seven families with individuals affected with PTC and other cancer types. Screening for DNA variants in shelterin genes was performed by using whole genome sequencing data from 17 families and WES data from 7 further families. Results: The TINF2 mutation (TINF2 p.Trp198fs) showed complete co-segregation with PTC and melanoma in the key family. The mutation is not reported in databases and not identified in 23 other families we screened. The expression of TINF2 was borderline reduced in individuals with the mutation. The truncated TINF2 protein showed abolished binding to TERF1. The RTL in the individuals with the mutation was significantly longer when compared with those without the mutation from the same family as well as compared with 62 healthy controls. Among the 24 families, we identified 3 missense and 1 synonymous variant(s) in 2 shelterin genes (TINF2 and ACD). Conclusions: The rare frameshift mutation in the TINF2 gene and the associated longer telomere length suggest that dysregulated telomeres could be a mechanism predisposing to PTC and melanoma. DNA coding variants in shelterin genes are rare. Further studies are required to evaluate the roles of variants in shelterin genes in thyroid cancer and melanoma.
Background: Our genome sequencing analysis revealed a frameshift mutation in the shelterin gene TINF2 in a large family with individuals affected with papillary thyroid carcinoma (PTC) and melanoma. Here, we further characterized the mutation and screened for coding variants in the 6 shelterin genes in 24 families. Methods: Sanger sequencing was performed to screen for the TINF2 mutation in the key family. Quantitative reverse transcription-polymerase chain reaction (PCR) was used for TINF2 gene expression analysis. Exogenous expression and co-immunoprecipitation techniques were used for assessing TINF2 binding to TERF1. Relative telomere length (RTL) was quantified in DNAs from lymphocytes by using quantitative real-time PCR. Whole exome sequencing (WES) was performed in seven families with individuals affected with PTC and other cancer types. Screening for DNA variants in shelterin genes was performed by using whole genome sequencing data from 17 families and WES data from 7 further families. Results: The TINF2 mutation (TINF2 p.Trp198fs) showed complete co-segregation with PTC and melanoma in the key family. The mutation is not reported in databases and not identified in 23 other families we screened. The expression of TINF2 was borderline reduced in individuals with the mutation. The truncated TINF2 protein showed abolished binding to TERF1. The RTL in the individuals with the mutation was significantly longer when compared with those without the mutation from the same family as well as compared with 62 healthy controls. Among the 24 families, we identified 3 missense and 1 synonymous variant(s) in 2 shelterin genes (TINF2 and ACD). Conclusions: The rare frameshift mutation in the TINF2 gene and the associated longer telomere length suggest that dysregulated telomeres could be a mechanism predisposing to PTC and melanoma. DNA coding variants in shelterin genes are rare. Further studies are required to evaluate the roles of variants in shelterin genes in thyroid cancer and melanoma.
Authors: Yanqiang Wang; Sandya Liyanarachchi; Katherine E Miller; Taina T Nieminen; Daniel F Comiskey; Wei Li; Pamela Brock; David E Symer; Keiko Akagi; Katherine E DeLap; Huiling He; Daniel C Koboldt; Albert de la Chapelle Journal: Thyroid Date: 2019-05-13 Impact factor: 6.568
Authors: F Canzian; P Amati; H R Harach; J L Kraimps; F Lesueur; J Barbier; P Levillain; G Romeo; D Bonneau Journal: Am J Hum Genet Date: 1998-12 Impact factor: 11.025
Authors: Carla Daniela Robles-Espinoza; Mark Harland; Andrew J Ramsay; Lauren G Aoude; Víctor Quesada; Zhihao Ding; Karen A Pooley; Antonia L Pritchard; Jessamy C Tiffen; Mia Petljak; Jane M Palmer; Judith Symmons; Peter Johansson; Mitchell S Stark; Michael G Gartside; Helen Snowden; Grant W Montgomery; Nicholas G Martin; Jimmy Z Liu; Jiyeon Choi; Matthew Makowski; Kevin M Brown; Alison M Dunning; Thomas M Keane; Carlos López-Otín; Nelleke A Gruis; Nicholas K Hayward; D Timothy Bishop; Julia A Newton-Bishop; David J Adams Journal: Nat Genet Date: 2014-03-30 Impact factor: 38.330
Authors: Mark M Iles; D Timothy Bishop; John C Taylor; Nicholas K Hayward; Myriam Brossard; Anne E Cust; Alison M Dunning; Jeffrey E Lee; Eric K Moses; Lars A Akslen; Per A Andresen; Marie-Françoise Avril; Esther Azizi; Giovanna Bianchi Scarrà; Kevin M Brown; Tadeusz Dębniak; David E Elder; Eitan Friedman; Paola Ghiorzo; Elizabeth M Gillanders; Alisa M Goldstein; Nelleke A Gruis; Johan Hansson; Mark Harland; Per Helsing; Marko Hočevar; Veronica Höiom; Christian Ingvar; Peter A Kanetsky; Maria Teresa Landi; Julie Lang; G Mark Lathrop; Jan Lubiński; Rona M Mackie; Nicholas G Martin; Anders Molven; Grant W Montgomery; Srdjan Novaković; Håkan Olsson; Susana Puig; Joan Anton Puig-Butille; Graham L Radford-Smith; Juliette Randerson-Moor; Nienke van der Stoep; Remco van Doorn; David C Whiteman; Stuart MacGregor; Karen A Pooley; Sarah V Ward; Graham J Mann; Christopher I Amos; Paul D P Pharoah; Florence Demenais; Matthew H Law; Julia A Newton Bishop; Jennifer H Barrett Journal: J Natl Cancer Inst Date: 2014-09-17 Impact factor: 11.816
Authors: Matthew N Bainbridge; Georgina N Armstrong; M Monica Gramatges; Alison A Bertuch; Shalini N Jhangiani; Harsha Doddapaneni; Lora Lewis; Joseph Tombrello; Spyros Tsavachidis; Yanhong Liu; Ali Jalali; Sharon E Plon; Ching C Lau; Donald W Parsons; Elizabeth B Claus; Jill Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Daniel Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Kyle M Walsh; Faith G Davis; Rose Lai; Sanjay Shete; Kenneth Aldape; Christopher I Amos; Patricia A Thompson; Donna M Muzny; Richard A Gibbs; Beatrice S Melin; Melissa L Bondy Journal: J Natl Cancer Inst Date: 2014-12-07 Impact factor: 11.816
Authors: Susanna Koivuluoma; Sandra Vorimo; Tiina M Mattila; Anna Tervasmäki; Timo Kumpula; Outi Kuismin; Robert Winqvist; Jukka Moilanen; Tuomo Mantere; Katri Pylkäs Journal: Fam Cancer Date: 2022-05-20 Impact factor: 2.375
Authors: Tsz-Kwong Man; Geraldine Aubert; Melissa A Richard; Wanda LeJeune; Elmira Hariri; Tatiana Goltsova; Amos Gaikwad; Yan Chen; Jillian Whitton; Wendy M Leisenring; Michael A Arnold; Joseph P Neglia; Yutaka Yasui; Leslie L Robison; Gregory T Armstrong; Smita Bhatia; Maria M Gramatges Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-15 Impact factor: 4.090
Authors: Isabelle Schmutz; Arjen R Mensenkamp; Kaori K Takai; Maaike Haadsma; Liesbeth Spruijt; Richarda M de Voer; Seunga Sara Choo; Franziska K Lorbeer; Emma J van Grinsven; Dirk Hockemeyer; Marjolijn Cj Jongmans; Titia de Lange Journal: Elife Date: 2020-12-01 Impact factor: 8.140
Authors: Luis Eduardo Barbalho de Mello; Thaise Nayane Ribeiro Carneiro; Aline Neves Araujo; Camila Xavier Alves; Pedro Alexandre Favoretto Galante; Vanessa Candiotti Buzatto; Maria das Graças de Almeida; Karina Marques Vermeulen-Serpa; Sancha Helena de Lima Vale; Fernando José de Pinto Paiva; José Brandão-Neto; Janete Maria Cerutti Journal: Endocr Connect Date: 2022-01-31 Impact factor: 3.335